{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-22-000023","form_type":"8-K/A","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2022-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.386456+00:00","generated_at":"2026-06-24T11:52:40.884166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biogen Q2 GAAP EPS $7.24, revenue $2.59B down 7% YoY; raises FY2022 guidance","bullets":["Revenue $2,589M (-7% YoY); GAAP EPS $7.24, Non-GAAP EPS $5.25.","MS revenue $1,719M (-4% YoY); SPINRAZA $431M (-14%); Biosimilars $194M.","FDA Priority Review for lecanemab in early Alzheimer's; decision by Jan 6, 2023; Phase 3 data expected Fall 2022.","Positive Phase 3 for zuranolone in PPD; joint US filing for MDD and PPD expected H2 2022.","Company raises full year 2022 financial guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-22-000023","json":"https://secwatch.observer/filing/0000875045-22-000023.json","markdown":"https://secwatch.observer/filing/0000875045-22-000023.md","text":"https://secwatch.observer/filing/0000875045-22-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504522000023/0000875045-22-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504522000023/biib-20220720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:52:40.884166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}